LNTH at a glance
Lantheus Holdings, Inc. (LNTH, SEC CIK 1521036) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Lantheus Holdings, Inc. (LNTH) reported revenue of $1.5 billion (up 0.5% from FY2024) and net income of $233.6 million. Diluted EPS was $3.41.
- As of September 30, 2026, 34 institutional investment managers tracked by SignalX reported holding Lantheus Holdings, Inc. (LNTH) shares worth $2.6 billion in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $1.5B
- +0.5% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 34 funds
- $2.6B · +0 vs prior quarter
- Latest 8-K
- Nov 10, 2026
- Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Development, manufacturing, and commercialization of radiopharmaceutical and diagnostic imaging products
- New launches: Acquisitions of Life Molecular (Neuraceq) and Evergreen, adding diagnostic imaging and CDMO services to portfolio in 2025
- Strategic shifts: Discontinued AZEDRA in Q1 2024, sold TechneLite in 2026, focusing on higher-growth assets like Neuraceq and CDMO services
- Notable metric: General & administrative expenses up $81.4M (42%) in 2025 due to acquisitions and litigation costs
- Distinct fact: Paid $250M upfront for PNT2002 license but ceased development, deciding not to pursue NDA or further investment
Risk Factors
- No specific or timely regulatory or legal risk detailed in the text
- No concrete geopolitical or macroeconomic threat exposure disclosed
- Operational risk from cybersecurity and data privacy requiring quarterly monitoring and oversight by Audit Committee
- No named competitor or technology disrupting market environment mentioned
- Key-person risk with CIO and CISO critical for risk management, each having ~30 years of industry experience
Management Discussion & Analysis
- Operating cash flow $390.1M in 2025 vs $544.8M in 2024, decrease driven by acquisitions and working capital timing
- Investing cash outflow $627.1M in 2025 vs $204.5M in 2024, 2025 includes $268.9M for Evergreen and $306.7M for Life Molecular acquisitions
- Financing cash used $316.5M in 2025 vs $115.7M in 2024, due to $300M stock repurchase in 2025 vs $100M in 2024
- Management highlights increased credit facility to $750M with extended maturity to 2029, expects cash plus credit availability to cover needs next 12+ months
AI summary of the LNTH 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- New merger risk: FTC Second Request on October 21, 2026 extended HSR review and could require divestitures or block closing
- Regulatory risk: LNTH-2501 FDA Complete Response Letter cited unresolved third-party manufacturing conditions
- Operational risk: PYLARIFY TruVu launch depends on PMF technology transfers, FDA approvals, and customer adoption beginning Q4 2026
- Financial risk: merger termination fee of $228.0 million could reduce cash available for general corporate purposes
- Asset risk: LNTH-2620 and LNTH-2515 impairment charges totaled $31.0 million after TAUKLARIFY approval changed development plans
Management Discussion & Analysis
- Revenue $389.9M, up 1.5% YoY from $384.0M
- Net income $22.4M, down 19.4% YoY from $27.8M
- Best segment Neurology: Neuraceq revenue $45.6M, up 123.0% YoY
- Operating margin 8.3% vs 11.4% YoY, calculated from reported operating income and revenue
- Cash $683.6M; nine-month operating cash flow $319.3M vs $300.0M, no 2026 share repurchases
- Near-term headwinds: PYLARIFY price decline, competition, LNTH-2501 CRL, Merger regulatory approvals pending
AI summary of the LNTH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Definitive agreement to sell CDMO business and Springfield, New Jersey facility to PharmaLogic
- Sale remains subject to customary closing conditions and potential regulatory approvals
Item 2.02: Results of Operations and Financial Condition
- Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026
- Full operating results, financial figures, and management commentary in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q3 revenue $389.9M, up 1.5%, with Neuraceq up 123.0% and PYLARIFY down 0.7%
- Adjusted EPS $1.68, up 32.3%, while GAAP EPS fell to $0.33 from $0.41
Item 8.01: Other Events
- FTC issued Second Requests on October 21, extending HSR review of Lantheus’s proposed merger with Curium
- Waiting period extends 30 days after both parties substantially comply, unless terminated sooner by the FTC
AI summaries of LNTH 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for LNTH
Don't miss the next LNTH filing
- Alerts as it files. A push when LNTH files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut LNTH, by share count.
- Ask anything. An AI agent that reads every LNTH filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Heino Mary Anne | F | Nov 17, 2026 | 6,206 | $101.80 |
| Marshall Robert J. Jr. | F | Aug 31, 2026 | 721 | $100.96 |
| Dinkelborg Ludger | F | Aug 17, 2026 | 2,536 | $100.91 |
| Brown Kimberly | F | Aug 17, 2026 | 463 | $100.91 |
| Baylor-Henry Minnie | A | May 14, 2026 | 4,137 | - |
| Thrall James H | A | May 14, 2026 | 4,137 | - |
| Pruden Gary J | A | May 14, 2026 | 4,137 | - |
| LENO SAM R | A | May 14, 2026 | 4,137 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $1.5B | $1.5B |
| Gross Profit | $709.5M | $988.3M | $942.0M |
| Operating Income | - | $457.0M | $310.8M |
| Net Income | $326.7M | $312.4M | $233.6M |
| Gross Margin | - | 64.4% | 61.1% |
| Op. Margin | - | 29.8% | 20.2% |
| Net Margin | - | 20.4% | 15.2% |
| Balance Sheet | |||
| Total Assets | $1.7B | $2.0B | $2.2B |
| Equity | - | $1.1B | $1.1B |
| ROE | - | 28.7% | 21.4% |
| Per Share | |||
| EPS | $4.65 | $4.36 | $3.41 |
| Cash Flow | |||
| Operating CF | - | $544.8M | $390.1M |
Source: XBRL data in Lantheus Holdings, Inc. (LNTH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate LNTH share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 34 | $2.65B |
| Q2 2026 | 34 | $3.66B |
| Q1 2026 | 33 | $2.31B |
| Q4 2025 | 31 | $2.11B |
| Q3 2025 | 34 | $1.81B |
| Q2 2025 | 32 | $2.76B |
| Q1 2025 | 33 | $2.16B |
| Q4 2024 | 28 | $1.77B |
- Millennium Management+1.65M (+492%)
- BlackRock+259.7K (+3%)
- Goldman Sachs Group+152.0K (+19%)
- Principal Financial Group+76.3K (+32%)
- Raymond James Financial+39.6K (+17%)
- T. Rowe Price Group−1.81M (-95%)
- Morgan Stanley−1.26M (-73%)
- Citadel Advisors LLC−730.4K (-53%)
- Dimensional Fund Advisors−492.1K (-34%)
- JPMorgan Chase & Co−436.4K (-62%)
- Soros Fund Management+364.0K
- Renaissance Technologies LLC+126.4K
- Two Sigma Investments+87.5K
- FMR LLC (Fidelity)−3.88M
- Truist Financial−3.3K
- Equitable Holdings Inc−2.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 259 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
LNTH filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 19, 2026 | - | - | - |
| 8-K | Nov 10, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 8-K | Oct 22, 2026 | - | Analysis | - |
| 8-K | Oct 14, 2026 | - | Analysis | - |
| 8-K | Oct 2, 2026 | - | Analysis | - |
| 8-K | Sep 21, 2026 | - | Analysis | - |
| SC 13G | Sep 4, 2026 | - | - | |
| SC 13D | Sep 4, 2026 | - | - | |
| 4 | Sep 2, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| SC 13G | Jul 31, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - |
Related Health Care companies
- TKNO · Alpha Teknova, Inc.In Vitro & In Vivo Diagnostic Substances
- CLDX · Celldex Therapeutics, Inc.In Vitro & In Vivo Diagnostic Substances
- IDXX · Idexx LaboratoriesIn Vitro & In Vivo Diagnostic Substances
- NTLA · Intellia Therapeutics, Inc.In Vitro & In Vivo Diagnostic Substances
- MYGN · MYRIAD GENETICS INCIn Vitro & In Vivo Diagnostic Substances
- NEOG · NEOGEN CORPIn Vitro & In Vivo Diagnostic Substances
- QDEL · QuidelOrtho CorpIn Vitro & In Vivo Diagnostic Substances
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
LNTH SEC filings: frequently asked questions
Which institutions hold LNTH stock?
As of September 30, 2026, the largest Lantheus Holdings, Inc. (LNTH) holders among the 13F filers tracked by SignalX were BlackRock ($861.7 million), Vanguard Portfolio Management LLC ($311.5 million), Vanguard Capital Management LLC ($290.6 million), State Street Corp ($248.0 million), Millennium Management ($198.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was LNTH's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Lantheus Holdings, Inc. (LNTH) reported revenue of $1.5 billion (up 0.5% from FY2024) and net income of $233.6 million. Diluted EPS was $3.41. The figures come from the XBRL data in the 10-K.
What are the main risks in LNTH's latest 10-K?
In the 10-K filed February 26, 2026, Lantheus Holdings, Inc. (LNTH) flagged: No specific or timely regulatory or legal risk detailed in the text. No concrete geopolitical or macroeconomic threat exposure disclosed. (AI summary of the Risk Factors section.)
What did LNTH report in its latest 8-K?
Lantheus Holdings, Inc. (LNTH) filed an 8-K on November 10, 2026 reporting Item 8.01 (Other Events). Definitive agreement to sell CDMO business and Springfield, New Jersey facility to PharmaLogic.
What are the latest LNTH SEC filings?
Lantheus Holdings, Inc. (LNTH) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on November 19, 2026.
What is LNTH's SEC CIK number?
Lantheus Holdings, Inc. (LNTH)'s SEC Central Index Key (CIK) is 1521036. EDGAR lists every LNTH filing under that number.
Ask anything about LNTH
The research agent reads LNTH's filings, financials, insider trades and 13F holders, then answers with sources.